CMS biosimilar coverage is at odds with its own biologics policy

via BioWorld
November 3, 2015
By Mari Serebrov

In a move that could hamstring the U.S. biosimilars market before it has a chance to fully open its doors, the Centers for Medicare & Medicaid Services (CMS) is sticking to a Part B biosimilars payment policy that would create a bifurcated biologics scheme when older proteins such as insulin and growth hormone are brought under the Biologics Price Competition and Innovation Act (BPCIA) in 2020, Pfenex Inc. CEO Bert Liang told BioWorld Today.

Read Full Article >